CJC-1295 No DAC / Modified GRF 1-29 (5 mg Vial) Dosage Protocol
CJC-1295 No DAC (also called Modified GRF 1-29) is a stabilized synthetic analog of GHRH(1-29) without the Drug Affinity Complex. Its half-life of approximately 30 minutes produces short, targeted GH pulses aligned with the natural pulsatile release pattern. Often combined with GHRPs (ipamorelin, GHRP-2) for synergistic GH amplification.
âš¡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous | Frequency: 1–3× daily, empty stomach
| Week | Dose Per Injection | Frequency | U-100 Units | Notes |
|---|---|---|---|---|
| Weeks 1–2 | 100 mcg | Once daily | 6 units | Starting dose |
| Weeks 3–4 | 200 mcg | Once or twice daily | 12 units | |
| Weeks 5–16 | 200–300 mcg | 2–3× daily | 12–18 units | Target range; combine with GHRP |
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the vial; avoid foaming.
- Gently swirl until dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.
Supplies Planning
| Item | 8 Weeks (200 mcg 2×/day) | 12 Weeks |
|---|---|---|
| CJC-1295 No DAC vials (5 mg) | 5–6 vials | 8–9 vials |
| Insulin syringes (30–50 unit) | 112 | 168 |
| Bacteriostatic water (10 mL) | 2 × 10 mL | 3 × 10 mL |
| Alcohol swabs | 2–3 × 100-pack | 3–4 × 100-pack |
Mechanism of Action
CJC-1295 No DAC (Modified GRF 1-29) contains the same tetrasubstituted GHRH(1-29) core as the DAC version — with stabilizing mutations at positions 2, 8, 15, and 27 — but without the albumin-binding DAC modification. This gives it a half-life of approximately 20–30 minutes, similar to natural GHRH.
The short half-life means it produces a targeted, physiologically-timed GH pulse rather than sustained GH elevation. This better mimics the body's natural pulsatile GH pattern and is preferred in protocols where preserving GH axis sensitivity is important. When co-administered with a GHRP (which acts through a completely different receptor — the ghrelin receptor), the two compounds produce synergistic GH release that is 3–5× greater than either compound alone. This is because GHRH and ghrelin receptor pathways converge on the same pituitary somatotrope cells through complementary intracellular signaling cascades.
Research Findings & Safety Profile
- Produces targeted GH pulses mimicking natural pulsatile release — shorter half-life preserves GH axis feedback sensitivity.
- Synergistic with GHRPs: combined CJC-1295 No DAC + ipamorelin produces 3–5× more GH than either alone.
- 100 mcg is considered the saturation dose — increasing beyond this shows diminishing returns in pituitary GH output.
- Must be timed carefully around food intake (2+ hours post-meal, or pre-sleep) for maximal effect.
- Lower water retention profile than CJC-1295 DAC due to pulsatile rather than sustained GH exposure.
- Possible effects: tingling/paresthesia, transient water retention, headache, fatigue.
Storage
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months | Dry, dark conditions |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days | Avoid freeze-thaw; protect from light |